P25. Characteristics, treatment options, and predictors of clinical failure among Pseudomonas aeruginosa infection with microbiologically confirmed intermediate or resistant carbapenem susceptibility profile: a multicenter clinical experience on behalf of CASPER (CArbapenem-reSistant <i>Pseudomonas aERuginosa</i> during and after the COVID-19 pandemic) study group
Andrea Dessilani(University of Modena and Reggio Emilia), Marianna Meschiari(Azienda Ospedaliero-Universitaria di Modena), Mario Sarti(Azienda Ospedaliero-Universitaria di Modena), Alessandra Oliva(Sapienza University of Rome), Shaniko Kaleci(University of Modena and Reggio Emilia), Lucia Serio(University of Modena and Reggio Emilia), Erica Franceschini(University of Modena and Reggio Emilia), Sergio Mezzadri(Azienda Sanitaria Unità Locale di Reggio Emilia), Maurizio Del Monte(Sapienza University of Rome), Gabriella Orlando(University of Modena and Reggio Emilia), Massimo Girardis(University of Modena and Reggio Emilia), Claudia Venturelli(Azienda Ospedaliero-Universitaria di Modena), Lesley De Pietri(Azienda Unita' Sanitaria Locale Di Modena), L Benassi, Cristina Mussini(University of Modena and Reggio Emilia), Maria Cristina Albertini(University of Urbino), Emanuela Biagioni(University of Modena and Reggio Emilia), M Codeluppi(Guglielmo da Saliceto Hospital), Andrea Bedini(Azienda Ospedaliero-Universitaria di Modena), Gabriele Melegari(Azienda Ospedaliero-Universitaria di Modena)
Cited by 0
Related Papers
Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population
|Clinical Infectious Diseases|2011|1.3k
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia
|Nature Communications|2020|846
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738
Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial
|Clinical Infectious Diseases|2018|424